| Project/Area Number |
17K11169
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Tokyo Metropolitan Tama Medical Center (Department of Clinical Research) |
|---|
Principal Investigator |
AZUMA TAKESHI 東京都立多摩総合医療センター(臨床研究・教育研修センター(臨床研究部)), 泌尿器科, 部長 (50719854)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
久米 春喜 東京大学, 医学部附属病院, 教授 (10272577)
佐藤 雄二郎 東京都立多摩総合医療センター(臨床研究・教育研修センター(臨床研究部)), 泌尿器科, 医員 (40770871)
|
|---|
| Project Period (FY) |
2017-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2019: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2018: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2017: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
|
|---|
| Keywords | B7-Ｈ３ / 膀胱癌 / イムノチェックポイント分子 / 腫瘍免疫 / イムノチェックポイント / B7－H3 / B7ーH3 / B7-H3 / 尿路悪性腫瘍 / 腫瘍学 |
|---|
| Outline of Final Research Achievements |
We detected high levels of sB7-H3 in the sera of 47% of patients with NMIBC versus only 8% in healthy donors. The increase of sB7-H3 was significantly associated with poor RFS and PFS. Multivariate analysis showed that elevated sB7-H3 was an independent prognostic factor of RFS and PFS. According to the European Organization for Research and Treatment of Cancer (EORTC), in intermediate-low and intermediate-high risk groups, the presence of sB7-H3 significantly determined the rate of recurrence and progression.
|
| Academic Significance and Societal Importance of the Research Achievements |
血清中の可溶型B7-H3濃度は有効な血清腫瘍マーカーになりうることが示唆された。
日常診療において、表在性膀胱癌の再発と進行の予測の精度が改善された。
|
